ATS/IDSA-2019 recommendations for the management of adult patients with community-acquired pneumonia: 12 years later


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Community-acquired pneumonia (CAP) remains the one of the leading causes of morbidity and mortality worldwide. In 2019, ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) consensus recommendations for the management of adult patients with CAP were published. Previous ATS/IDSA recommendations came out 12 years ago. The article discusses the main provisions of the new revision of the ATS/IDSA consensus recommendations, in some cases - in comparison with the position of Russian specialists. A brief analysis of the new ATS/IDSA-2019 recommendations suggests that the individual provisions contained therein differ only to a minimum extent from those in the 2007 recommendations. So, the key approaches to the diagnosis and treatment of CAP in adults, formulated at the beginning of the XXI century, remain relevant today

全文:

受限制的访问

作者简介

Alexander Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Email: aisyn@list.ru
Dr. Sci. (Med.), Professor, Head of the Department of Pulmonology 2/1, build. 1, Barrikadnaya str., Moscow 125993, Russian Federation

参考

  1. Torres A., Cillniz C., Biasi F., et al. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. Respir Med. 2018;137:6-13. doi: 10.1016/j.rmed.2018.02.007.
  2. Ferreira-Coimbra J., Sarda C., Rello J. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther. 2020;37:1302-18. doi: 10.1007/s12325-020-01248-7.
  3. Peyrani P., Mandell L., Torres A., Tillotson G.S. The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. Expert Rev Respir Med. 2019;13:139-52. doi: 10.1080/17476348.2019.1562339.
  4. Triana A.J., Molinares J.L., Del Rio-Pertuz G. Clinical practice guidelines for the management of community-acquired pneumonia: A critical appraisal using the AGREE II instrument. Int J Clin Pract. 2020;74:e13478. Doi: 10.1111/ ijcp.13478.
  5. Mandell L., Niederman M. Canadian Community Acquired Pneumonia Consensus Conference Group. Antimicrobial treatment of community acquired pneumonia in adults: A conference report. Can J Infect Dis. 1993;4:25-8.
  6. Niederman M.S., Bass J.B. Jr, Campbell G.D., et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 1993;148:1418-26.
  7. Чучалин А.Г., Синопальников А.И., Яковлев С.В. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клиническая микробиология и антимикробная химиотерапия. 2003;5:198-224.
  8. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клиническая микробиология и антимикробная химиотерапия. 2006;8:54-86.
  9. Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике (Пособие для врачей). Клиническая микробиология и антимикробная химиотерапия. 2010;12:186-225.
  10. Чучалин А.Г., Синопальников А.И., Козлов Р.С., Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Клиническая микробиология и антимикробная химиотерапия. 2015;17:84-126.
  11. Внебольничная пневмония. Клинические рекомендации МЗ РФ (проект). www.antibiotic.ru.
  12. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am J Respir Crit Care Med. 2001;163:1730-54. Doi: 10.1164/ ajrccm.163.7.at1010.
  13. Bartlett J.D., Dowell S.F., Mandell L.A., et al. Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-82. doi: 10.1086/313954.
  14. Mandell L.A., Marrie T.J., Grossman R.E., et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31:383-421.
  15. Grupo de Trabajo de Asociacion Latinoamericana del Torax (ALAT). Recomendaciones ALAT sobre la neumonia adquirida en la communidad. Arch Bronconeumol. 2001;37:340-48.
  16. Working Groups of the South African Pulmonology Society and the Antibiotic Study Group of South Africa. Management of community-acquired pneumonia in adults. S Afr Med J. 1996;86: 1152-63.
  17. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax. 2001;56(Suppl IV):1-64.
  18. Paul Ehrlich Society for Chemotherapy and the German Respiratory Association. Rational treatment of bacterial respiratory tract infections. Chemother J. 2000;9:3-23.
  19. Dorca J., Bello S.,Blanquer J., et al. Diagnostico y tratamiento de la neumonia adguirida en la comunidad. Arch Bronconeumol. 1997;33:240-46.
  20. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138-80. doi: 10.1183/09031936.05.00055705.
  21. Memish Z.A., Shibl A.M., Ahmed Q.A.A., and The Saudi Arabian Community-Acquired pneumonia Working Group (SACAPWG). Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. Int J Antimicrob Agents. 2002;20:1-12. doi: 10.1016/s0924-8579(02)00243-1.
  22. Matsushima T., Kohno S., Saito A., et al. Diagnostic and treatment guigeline for community-acquired pneumonia. Tokyo: Japanese Respiratory Society, General Managing Director Ando Massayuki; 2000. Int J Antimicrob Agents. 2001;18:45-8.
  23. Correa R.A., Costa A.N., Lundgren F., et al. 2018 recommendations for the management of community acquired pneumonia. J Bras Pneumol. 2018;44:405-23. doi: 10.1590/S1806-37562018000000130.
  24. Cao B., Huang Y., She D.-Y., et al. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2017. Doi: 10.1111/ crj.12674.
  25. Lee M.S., Oh J.Y., Kang C.-I., et al. Guideline for Antibiotic Use in Adults with Community-acquired Pneumonia. Infect Chemother. 2018;50:160-98. doi: 10.3947/ic.2018.50.2.160.
  26. Wiersinga W.J., Bonten M.J., Boersma W.G., et al. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J Med. 2018;76:4-13.
  27. Athlina S., Lidmanc C., Lundqvis A., et al. Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. Infect Dis. 2017;0:1-26.
  28. Metlay J.P., Waterer G.W., Long A.C., et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(Iss 7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
  29. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27-S72.
  30. Sato T., Aoshima M., Ohmagari N., Tada H., Chohnabayashi N. Usefulness of sputum Gram staining in community-acquired pneumonia [in Japanese]. Nihon Kokyuki Gakkai Zasshi. 2002;40:558-63.
  31. Shariatzadeh M.R., Marrie T.J. Does sputum culture affect the management and/or outcome of community-acquired pneumonia? East Mediterr Health J. 2009;15:792-99.
  32. Uematsu H.,Hashimoto H.,Iwamoto T.,Horiguchi H., Yasunaga H. Impact of guideline-concordant microbiological testing on outcomes of pneumonia. Int J Qual Health Care. 2014;26:100-7. doi: 10.1093/intqhc/mzt078.
  33. Lidman C., Burman L.G., Lagergren A., Ortqvist A. Limited value of routine microbiological diagnostics in patients hospitalized for community-acquired pneumonia. Scand J Infect Dis. 2002;34:873-79. doi: 10.1080/0036554021000026967.
  34. Sanyal S., Smith P.R., Saha A.C., et al. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med. 1999;160:346-48. doi: 10.1164/ajrccm.160.1.9806048.
  35. Falguera M., Ruiz-Gonz'alez A., Schoenenberger J.A., et al. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia. Thorax. 2010;65:101-6.
  36. van der Eerden M.M., Vlaspolder F., de Graaff C.S., et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax. 2005 60:672-78.
  37. Charles P.G.P., Wolfe R., Whitby M., et al. SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia. Clin Infect Dis. 2008;47:375-84. doi: 10.1086/589754.
  38. https://www.map.antibiotic.ru
  39. Иванчик Н.В., Чагарян А.Н., Сухорукова М.В. и др. Антибиотикорезистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПеГАС 2014-2017». Клиническая микробиология и антимикробная химиотерапия. 2019;3:230-37.
  40. Postma D.F., van Werkhoven C.H., van Elden L.J., et al. Antibiotic treatment strategies for community- acquired pneumonia in adults. N Engl J Med. 2015;372:1312-23. Doi: 10.1056/ NEJMoa1406330.
  41. Garin N., Genne D., Carballo S., et al. B-Lactam monotherapy vs b-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174:1894-1901.
  42. Carreno J.J., Lodise T.P Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE. Infect Dis Ther. 2014;3:123-32. doi: 10.1007/s40121-014-0036-8.
  43. Grau S., Lozano V, Valladares A., et ai. Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain. Clinicoecon Outcomes Res. 2014;6:83-92. doi: 10.2147/CEOR.S55265.
  44. Mortensen E.M., Copeland L.A., Pugh M.J., et al. Diagnosis of pulmonary malignancy after hospitalization for pneumonia. Am J Med. 2010;123:66-71. doi: 10.1016/j.amjmed.2009.08.009.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##